Joint Comments Regarding NIH Exclusive License to Ziopharm Oncology for Cell Therapy

(Update: The NIH provided a response to our comments on July 16, 2020) On July 6, 2020, Knowledge Ecology International and the Union for Affordable Cancer Treatment submitted joint comments regarding the National Institutes of Health’s (NIH) proposed exclusive license… Continue Reading

KEI Comments Regarding NIH Exclusive License for Treatment of Cancer to NeoImmune Tech

On Friday April 17, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: The Development of Bispecific Antibodies Targeting Glypican 1 (GPC1) for the Treatment of… Continue Reading

KEI Comments Regarding NIH Exclusive License for Adoptive Cell Therapy to Lyell Immunopharma

On Friday April 17, 2020, Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) regarding the “Prospective Grant of an Exclusive Patent License: Methods and Compositions for Adoptive Cell Therapy” to Lyell Immunopharma, Inc. (85 FR… Continue Reading

KEI Comments Regarding NIH Exclusive License to TeraImmune for T Cell Therapy

(UPDATE: The NIH provided a response to our comments on February 25, 2020) On February 3, 2020, Knowledge Ecology International (KEI) submitted comments to the “Prospective Grant of Exclusive Patent License: Development of Regulatory T-Cell Therapies for the Treatment of… Continue Reading

KEI and UACT Comments to NIH on License to T-Cell Therapy for Cancer to Ziopharm Oncology

(Update: The NIH provided a response to our comments on November 15, 2019) On Friday October 18, 2019, Knowledge Ecology International and the Union for Affordable Cancer Treatment (UACT) submitted comments on the “Prospective Grant of an Exclusive Patent License:… Continue Reading